Researchers at Cancer Treatment Centers of America in suburban Chicago evaluating investigational medication for HER2-positive breast cancer

Cancer Treatment Centers of America® (CTCA) today announced it is enrolling patients in a clinical study designed to evaluate a potential new treatment option for patients with HER2-positive breast cancer. The hospital is the only center to offer the study north of Niles, Illinois, and is the closest location to Milwaukee, Wisconsin. The randomized pivotal study, called HER2CLIMB, will evaluate the investigational medication tucatinib in combination with standard treatments for patients with locally advanced or metastatic HER2-positive (HER2+) breast cancer, with or without brain metastases.